TY - JOUR
T1 - Combination chemotherapy of S-1 plus biweekly docetaxel for advanced and recurrent gastric cancer
AU - Takahashi, Ikuo
AU - Oki, Eiji
AU - Egashira, Akinori
AU - Morita, Masaru
AU - Kakeji, Yoshihiro
AU - Maehara, Yoshihiko
PY - 2006/6
Y1 - 2006/6
N2 - The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2%. The incidence of more than grade 3 adverse effects was 29%(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.
AB - The S-1 +biweekly docetaxel (DOC) combination therapy was evaluated for advanced or recurrent gastric cancer patients. This combination therapy was evaluated in vitro using the nude rat-gastric cancer xenograft system. S-1 alone or DOC alone showed antitumor activity, and the antitumor activity was synergistic when two drugs were combined. In clinical settings, the schedule was S-1 80 mg/m2 (day 1-14, orally) and DOC (day 1 and day 15, intravenously) followed by a 2-week rest. In phase I study, the dose of DOC was evaluated, and a recommended dose for phase II was determined as 35 mg/m2. The entry for phase II study was completed, and the preliminary results of 33 patients showed the response rate of 21.2%. The incidence of more than grade 3 adverse effects was 29%(neutropenia, leukocytopenia, anorexia and mucositis). The S-1 +biweekly DOC combination therapy can be a candidate for outpatient chemotherapy for advanced or recurrent gastric cancer.
UR - http://www.scopus.com/inward/record.url?scp=33747389384&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33747389384&partnerID=8YFLogxK
M3 - Review article
C2 - 16897979
AN - SCOPUS:33747389384
SN - 0385-0684
VL - 33 Suppl 1
SP - 87
EP - 90
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
ER -
